The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer
Crossref DOI link: https://doi.org/10.1007/s00280-016-3026-6
Published Online: 2016-04-21
Published Print: 2016-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Nishimura, Meiko
Toyoda, Masanori
Takenaka, Kei
Imamura, Yoshinori
Chayahara, Naoko
Kiyota, Naomi
Mukohara, Toru
Kotake, Takeshi
Tsuji, Akihito
Saito, Kosuke
Saito, Yoshiro
Minami, Hironobu
License valid from 2016-04-21